Literature DB >> 1905784

A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.

E A Padlan1.   

Abstract

It is proposed to reduce the immunogenicity of allogeneic antibody variable domains, while preserving ligand-binding properties, by reducing their antigenicity through replacement of the exposed residues in the framework regions which differ from those usually found in host antibodies. The results of a comparison of representative murine antibody sequences with those of human origin suggest that the number of residues that need to be replaced to "humanize" those antibodies could be small.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905784     DOI: 10.1016/0161-5890(91)90163-e

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  26 in total

Review 1.  Generation of recombinant antibodies.

Authors:  S M Kipriyanov; M Little
Journal:  Mol Biotechnol       Date:  1999-09       Impact factor: 2.695

Review 2.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

Review 3.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

4.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

5.  New engineered antibodies against prions.

Authors:  Nives Škrlj; Marko Dolinar
Journal:  Bioengineered       Date:  2013-08-09       Impact factor: 3.269

6.  Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Authors:  Paul J Domanski; Pratiksha R Patel; Arnold S Bayer; Li Zhang; Andrea E Hall; Peter J Syribeys; Elena L Gorovits; Dawn Bryant; John H Vernachio; Jeff T Hutchins; Joseph M Patti
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 7.  Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering.

Authors:  Cristina Parola; Daniel Neumeier; Sai T Reddy
Journal:  Immunology       Date:  2017-10-30       Impact factor: 7.397

8.  Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx.

Authors:  S Mao; C Gao; C H Lo; P Wirsching; C H Wong; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

9.  Humanization of murine monoclonal antibodies through variable domain resurfacing.

Authors:  M A Roguska; J T Pedersen; C A Keddy; A H Henry; S J Searle; J M Lambert; V S Goldmacher; W A Blättler; A R Rees; B C Guild
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

10.  Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

Authors:  S Stephens; S Emtage; O Vetterlein; L Chaplin; C Bebbington; A Nesbitt; M Sopwith; D Athwal; C Novak; M Bodmer
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.